CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment
SEOUL, South Korea, June 29, 2022 /PRNewswire/ – CanariaBio Inc. (developing its biotechnology assets through its subsidiaries, MH…